Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chemotherapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,819 result(s) found for: Chemotherapy. Displaying page 20 of 291.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    EudraCT Number: 2014-004432-18 Sponsor Protocol Number: Caremore-Trastuzumab Start Date*: 2015-02-18
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Activity of trastuzumab based chemotherapy in metastatic breast patients with HER2-negative primary tumor but HER2 positive circulating tumor cells (CareMore-Trastuzumab)
    Medical condition: Metastastic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001361-27 Sponsor Protocol Number: ICR-CTSU/2015/10054 Start Date*: 2016-09-21
    Sponsor Name:The Institute of Cancer Research
    Full Title: CTC-STOP: Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer.
    Medical condition: Advanced Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001198 Adenocarcinoma of the prostate metastatic LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-001933-16 Sponsor Protocol Number: 26866138PCR2002 Start Date*: 2007-03-13
    Sponsor Name:Christos N. Papandreou
    Full Title: "A Phase II, Open-Label study of Velcade(Bortezomib)for patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy"
    Medical condition: Treatment of patients with Androgen-Independent Prostate Carcinoma who progressed on or after prior chemotherapy.
    Disease:
    Population Age: Gender: Male
    Trial protocol: GR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003727-37 Sponsor Protocol Number: repos study Start Date*: 2008-05-20
    Sponsor Name:Haga Teaching Hospital
    Full Title: A randomized, open label, multicentre trial to define the most effective haemoglobin concentration to start erythropoietin beta (neoRecormon) therapy in anaemic subjects with lymphoproliferative ma...
    Medical condition: Anemia in cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004123-19 Sponsor Protocol Number: MUN-391-LOR-0050-I Start Date*: 2006-01-24
    Sponsor Name:Klinikum rechts der Isar der Technischen Universitaet Muenchen
    Full Title: Metabolic Response Evaluation for an Individualization of Neoadjuvant Chemo- and Radiotherapy in Esophageal Adenocarcinoma
    Medical condition: This study will test an optimized therapy for patients with chemotherapy-resistent locally advanced adenocarcinomas at the gastro-esophageal junction. According to the protocol, patients should re...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003995-36 Sponsor Protocol Number: STAD-1 Start Date*: 2006-10-04
    Sponsor Name:ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE "G. PASCALE"
    Full Title: A MULTICENTER RANDOMIZED PHASE III STUDY COMPARING FIXED DOSES WITH TOXICITY-ADJUSTED DOSES OF STANDARD CHEMOTHERAPY WITH CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY ADVANCED SMALL CELL LUNG CA...
    Medical condition: Small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059514 Small cell lung cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003950-24 Sponsor Protocol Number: EOX1.4 Start Date*: 2012-02-14
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: PHASE II TRIAL OF PALLIATIVE EPIRUBICIN, OXALIPLATIN & CAPECITABINE (EOX) CHEMOTHERAPY COMBINED WITH OMEGA-3 FISH OIL INFUSION (OMEGAVEN) IN PATIENTS WITH OESOPHAGO-GASTRIC CARCINOMA
    Medical condition: Unresectable oesophageal and/or gastric cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003324-36 Sponsor Protocol Number: NT14035-3/2013 Start Date*: 2013-11-07
    Sponsor Name:Charles University in Prague, Faculty of Medicine in Hradec Králové
    Full Title: Kinetically guided removal of plazma pegylated liposomal doxorubicin to enhance the benefit of cytostatic therapy of patients with ovarian cancer.
    Medical condition: Primary aim: enhanced therapeutic benefit of liposomal doxorubicin - a drug indicated for ovarian cancer resistant to chemotherapy with the first line drugs. This approach can be considered a model...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002337-19 Sponsor Protocol Number: STUDIODH-OMEOPATIA Start Date*: 2011-09-05
    Sponsor Name:AZIENDA UNITA' SANITARIA LOCALE DI PARMA
    Full Title: A PHASE II EXPLORATIVE STUDY EVALUATING ACTIVITY AND SAFETY OF HOMEOPATHIC MEDICINE ON CANCER RELATED FATIGUE (CRF) AND QUALITY OF LIFE IN ONCOLOGIC PATIENTS UNDER CHEMOTHERAPY IN DAY HOSPITAL AT ...
    Medical condition: Oncologic patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005216-24 Sponsor Protocol Number: DSHNHL2005-1 Start Date*: 2009-06-09
    Sponsor Name:University of Saarland
    Full Title: 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to...
    Medical condition: Relapse or primary progress of aggressive CD-20-positive-B-NHL
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052314 Lymphatic disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003907-20 Sponsor Protocol Number: C16051 Start Date*: 2019-07-10
    Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit
    Full Title: Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refract...
    Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005548-25 Sponsor Protocol Number: RNOP-12 Start Date*: 2008-07-28
    Sponsor Name:Freistaat Bayern, vertreten durch Klinikum der Universität Regensburg
    Full Title: Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in...
    Medical condition: Patients with high-grade gliomas (world health organisation [WHO] grade III or IV) in the first relapse after first-line therapy including chemotherapy with or without nitrososurea, with a life exp...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002850-38 Sponsor Protocol Number: PI-0327-2013 Start Date*: 2015-05-21
    Sponsor Name:FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA
    Full Title: EFFICACY AND SAFETY OF EARLY POSTOPERATIVE CHEMOTHERAPY INTRAPERITONEAL (EPIC) WITH PACLITAXEL IN THE RADICAL SURGERY TREATMENT OF OVARIAN PERITONEAL CARCINOMATOSIS
    Medical condition: ovarian peritoneal carcinomatosis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002324-27 Sponsor Protocol Number: MYL-1401H-3001 Start Date*: 2015-04-22
    Sponsor Name:Mylan GmbH
    Full Title: Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL 1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Che...
    Medical condition: chemotherapy-induced neutropenia in patients with stage II/III breast cancer receiving docetaxel, doxorubicin, and cyclophosphamide (TAC) anti-cancer chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004388-37 Sponsor Protocol Number: 69HCL19_0457 Start Date*: 2020-03-03
    Sponsor Name:Hospices Civils de Lyon
    Full Title: A Three-Cohort Phase II trial to Assess the Efficacy of a Maintenance Treatment with TALAzoparib following First Line Platinum-based Chemotherapy in Pleural and Malignant Peritoneal MESOthelioma Pa...
    Medical condition: This study involves adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma. The cohorts B1 will be patient populations with non-resected or incomp...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    21.0 100000004864 10034669 Peritoneal mesothelioma malignant advanced LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002576-27 Sponsor Protocol Number: ICM-URC2016/27 Start Date*: 2017-03-01
    Sponsor Name:Institut régional du Cancer de Montpellier
    Full Title: Lean body mass normalization of oxaliplatin based chemotherapy for stage III colon cancer patients treated in adjuvant satting: Impact on Oxaliplatin induced sensitive neurotoxicity. A multicenter ...
    Medical condition: colon cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009955 Colon cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002588-23 Sponsor Protocol Number: 2019/0407/HP Start Date*: 2023-03-13
    Sponsor Name:CHU de Rouen
    Full Title: Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy: A randomized phase III trial - COnCERTO (French 01-18)
    Medical condition: Patients first treated by stoma and requiring chemotherapy for obstructive colon cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    20.0 10042613 - Surgical and medical procedures 10073254 Neoadjuvant therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003969-18 Sponsor Protocol Number: D5162C00042 Start Date*: 2021-07-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with ...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005437-32 Sponsor Protocol Number: ERASE-TMZ Start Date*: 2021-03-10
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuva...
    Medical condition: Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001170 Adenocarcinoma of colon stage II LLT
    21.0 100000004864 10001171 Adenocarcinoma of colon stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000661-20 Sponsor Protocol Number: ICO Start Date*: 2019-05-31
    Sponsor Name:Vilnius University Hospital Santaros klinikos
    Full Title: Ivabradine to prevent anthracycline-induced cardiotoxicity: a prospective randomized open label clinical trial.
    Medical condition: Cancers treated with anthracyclines: leukemias, limphomas, breast, stomach, uterine, ovarian, lung.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 16  17  18  19  20  21  22  23  24  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 16:36:28 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA